Pharming Group NV (OTCMKTS:PHGUF – Get Free Report)’s share price hit a new 52-week low on Monday. The stock traded as low as $0.9285 and last traded at $0.9285, with a volume of 1,603 shares traded. The stock had previously closed at $1.1050.
Pharming Group Price Performance
The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.39. The stock has a market cap of $623.09 million, a price-to-earnings ratio of 77.38 and a beta of 0.42. The company’s fifty day moving average is $1.12 and its two-hundred day moving average is $1.28.
About Pharming Group
Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing medicines for rare diseases and other conditions with limited treatment options. The company was founded in 1988 and has built its business around therapies produced using recombinant technology.
Pharming’s principal product is Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially life-threatening swelling.
Recommended Stories
- Five stocks we like better than Pharming Group
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
- PepsiCo’s Earnings Beat Masks a Bigger Problem With Its North American Business
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
